Share Email Print

Journal of Biomedical Optics • Open Access

In vivo/ex vivo targeting of Langerhans cells after topical application of the immune response modifier TMX-202: confocal Raman microscopy and histology analysis
Author(s): Maxim E. Darvin; Gisela Thiede; Saul Mujica Ascencio; Sabine Schanzer; Heike Richter; Sabrina E. Vinzón; Daniel Hasche; Frank Rösl; Roberto May; Yohan Hazot; Dov Tamarkin; Juergen Lademann

Paper Abstract

The increased ability of TMX-202 (derivative of imiquimod) to penetrate the intact stratum corneum (SC) and the follicular orifices of porcine ear skin was shown ex vivo using confocal Raman microscopy and laser scanning microscopy. Moreover, to assess whether TMX-202 is able to reach the immune cells, Langerhans cells extracted from pretreated human skin were investigated ex vivo using confocal Raman microscopy combined with multivariate statistical methods. Tracking the Raman peak of dimethyl sulfoxide centered at 690  cm−1, the absorption of TMX-202 containing formulation by Langerhans cells was shown. To answer the question whether the TMX-202 active ingredient is able to reach Langerhans cells, the attraction of immune cells to TMX-202 containing formulation treated skin was measured in the in vivo rodent model Mastomys coucha. The results show that TMX-202 active ingredient is able to reach Langerhans cells after penetrating through the intact skin and subsequently attract immune cells. Both the intercellular/transcellular as well as the follicular pathways allow the penetration through the intact barrier of the SC.

Paper Details

Date Published: 27 May 2016
PDF: 8 pages
J. Biomed. Opt. 21(5) 055004 doi: 10.1117/1.JBO.21.5.055004
Published in: Journal of Biomedical Optics Volume 21, Issue 5
Show Author Affiliations
Maxim E. Darvin, Charité Universitätsmedizin Berlin (Germany)
Gisela Thiede, Charité Universitätsmedizin Berlin (Germany)
Saul Mujica Ascencio, Charité Universitätsmedizin Berlin (Germany)
Instituto Politécnico Nacional (Mexico)
Sabine Schanzer, Charité Universitätsmedizin Berlin (Germany)
Heike Richter, Charité Universitätsmedizin Berlin (Germany)
Sabrina E. Vinzón, Deutsches Krebsforschungszentrum (Germany)
Daniel Hasche, Deutsches Krebsforschungszentrum (Germany)
Frank Rösl, Deutsches Krebsforschungszentrum (Germany)
Roberto May, Telormedix S.A. (Switzerland)
Yohan Hazot, Foamix Ltd. (Israel)
Dov Tamarkin, Foamix Ltd. (Israel)
Juergen Lademann, Charité Universitätsmedizin Berlin (Germany)

© SPIE. Terms of Use
Back to Top